VistaGen Therapeutics Initiates PALISADE Phase 3 Trial of PH94B in Social Anxiety Disorder May 26, 2021
VistaGen Therapeutics Announces Appointment of Ann Cunningham as Chief Commercial Officer May 4, 2021
VistaGen Therapeutics Announces Appointment of Joanne Curley, Ph.D. to its Board of Directors Apr 27, 2021
VistaGen’s Poster Presentation at the Anxiety and Depression Association of America’s 2021 Annual Conference Differentiates PH94B’s Mechanism of Action from Highly-Addictive Benzodiazepines Mar 22, 2021
VistaGen’s PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical Study Mar 11, 2021
VistaGen Therapeutics Reports Fiscal 2021 Third Quarter Financial Results and Provides Update on Expected Clinical Studies in Calendar 2021 Feb 11, 2021
